2025 Sponsors

Lunit develops AI-powered medical image analysis software via cutting-edge deep learning technology. Our Lunit SCOPE product suite helps researchers and clinicians make accurate and efficient decisions through data-driven imaging biomarkers. Lunit SCOPE IO is our AI-powered analyzer of the tumor microenvironment, purely from H&E, for quantitative immune phenotyping and beyond. Peer reviewed studies employing SCOPE IO have been published in the Journal of Clinical Oncology, Clinical Cancer Research, NPJ Precision Oncology, and more. Lunit SCOPE IHC is our AI-powered analyzer of IHC targets including PD-L1, HER2, and more. Lunit SCOPE IHC currently powers all PD-L1 scoring for Guardant Health’s Galaxy PD-L1 tissue testing. Lunit works with the world’s leading biopharmaceutical companies, CROs, and clinical labs to develop and deploy the next generation of oncology therapeutic biomarkers.

NeoGenomics specializes in premier cancer solutions. We partner with pharmaceutical clients from discovery to commercialization with our broad oncology testing capabilities powered by in-house scientific expertise and dedicated project support teams. Our clients benefit from our state-of-the-art molecular technology, from whole exome sequencing, whole transcriptome sequencing, HLA typing, and the proprietary MultiOmyx™ high-order multiplexing methodology. We are the trusted experts with over 20 years of experience helping navigate the increasingly complex cancer landscape. For more information, visit https://neogenomics.com.

Scimega is a niche Canadian oncology CRO acting in Canada within the context of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs. Skilled in collaborative vendor teaming, Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of Lean Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the Lean trajectory.

To learn more about the Canadian opportunity or explore an expansion with Scimega, please visit: https://scimega.com/

TD2 provides innovative services for improved and accelerated development of medicines for cancer. Our team has deep experience and understanding in drug development. Preclinical development, combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. For more information, go to www.td2inc.com

MedQIA, WorldCare Clinical and DARC, have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s unique AI-based software platform integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. For more information, go to https://www.voiantclinical.com/

Leading scientists and researchers turn to Flywheel to accelerate their work and collaborate with ease. Our medical imaging AI platform streamlines the massive tasks of data discovery, aggregation, and curation; automates research workflows; and scales on demand.

At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy sequence data in studies around the globe. Our microarrays also provide accurate, high-throughput genotyping for a range of applications. The innovative products that we provide are facilitating breakthroughs in many scientific areas, including oncology, reproductive health, genetic disease, precision medicine, agriculture, microbiology, and beyond. The progress we see being made in genomics inspires us to push the boundaries of what is possible so we can create the next generation of genomics solutions. For more information, go to https://www.illumina.com/

MERIT is an oncology endpoint expert providing image collection, centralized reading, and data management services for clinical trials since 2012. We have supported hundreds of trials across 58 countries. MERIT partners with CROs as well as pharma and biotech companies to deliver reliable endpoint services in global clinical trials. To learn more, please visit meritcro.com

OCCAM Immune is a non-profit Academic Research Organization emerging from Mount Sinai Hospital that provides immune monitoring services for clinical trials. Its streamlined process, from contracting to data delivery, and its one-stop shop approach—from sample processing to assays and data analysis—bridge academic research excellence with industrial scalability. For more information, go to https://occam-immune.com/

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. Its proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC™ test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage. For more information, go to https://www.oncohost.com/

RadMD is a radiologist-led imaging provider focusing on blinded central and site reads with a specialty in oncology trials. “We will never lose focus on what has always been the most important task: the image reads. It is the reads that determine if a drug works. Everything else is secondary and supportive of the highest quality reads possible.” Rick Patt, Co-founder

For more information, visit https://www.stemcell.com/

Specialized in developing genetically engineered mouse models, GenoBioTX proudly offers an inventory of 9000 catalog mouse models and has successfully customized over 19,000 strains for clients. GenoBioTX also provide more than 600 humanized mouse models for drug discovery. Beyond this, GenoBioTX has expanded into pre-clinical CRO services across diverse disease areas, especially immuno-oncology. Our commitment to innovation and client satisfaction continues to drive our success in the dynamic field of drug discovery. For more information, go to https://www.modelorg.com/en/.

Image Analysis Group is a leading imaging Clinical Research Organization, combining medical expertise, a global team and the DYNAMIKA platform with embedded AI capabilities for data management and central review. For nearly 20 years, IAG supports pharma companies in developing novel drugs, using imaging to assess safety and efficacy. For more information, visit https://www.ia-grp.com/about-us/

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans. For more information, go to https://onc.ai/

Picture Health creates multimodal AI biomarkers for precision oncology via our proprietary Px Platform with next-generation radiomics capabilities.  Our advanced radiomic and pathomic imaging features, demonstrated in over 80 peer reviewed papers, are tied to interpretable biological tumor characteristics. Picture Health partners with biopharma companies to improve patient characterization & selection using small datasets from Phase 1 and 2 clinical trials. The Px Platform enables us to develop custom predictive AI biomarkers tailored to a specific indication. For more information, go to https://picturehealth.com/

Radiomics is an imaging research organization which focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Founded in 2016, Radiomics has its HQ in LégiaPark in Liege, Belgium and a North American office in Toronto, Canada. For more information, go to www.radiomics.bio

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development. For more information, go to https://rarecyte.com/